Cipla
Cipla delivered a strong Q4 FY26 with India business growing 15% YoY and North America revenue of $155M.
Cipla vs Piramal Pharma Q4 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Piramal Pharma
Piramal Pharma reported a transitional FY26 with revenue decline due to inventory destocking in a key on-patent commercial product, subdued biotech funding in H1, and intensified competition in inhalation anesthesia i...
Result Snapshot
Revenue₹6,541 Cr₹2,752 Cr
PAT₹543 Cr₹-9 Cr
EBITDA Margin15%—
Sentimentbullishneutral
Key Quotes
We are expecting to launch this product within the coming months. Our Goa facility together with two US facilities is well equipped to support the launch of all four respiratory assets planned for FI27.
We're currently anticipating revenue growth in the early to mid teens with EBITDA expected to grow faster than revenue supported by operating leverage.